EUCTR2017-003697-14-DK进行中（未招募）1 期
A randomised, double-blind, placebo-controlled, trial to evaluate the efficacy of brodalumab monotherapy on vascular and systemic inflammation by 18F-FDG-PET/CT in subjects with moderate-to-severe plaque-type psoriasis who are candidates for systemic therapy
Aarhus University Hospital0 个研究点目标入组 50 人开始时间: 2017年9月28日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written informed consent obtained from the subject prior to performing any protocol-related procedures.
- •2.Age 40 and above.
- •3.Diagnosis of chronic plaque psoriasis confirmed by a dermatologist
- •4.Psoriasis area severity index (PASI) = 10
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1.Non-Danish speaking
- •2.History of inflammatory bowel disease, arthritis (not including psoriatic arthritis), systemic lupus erythematosus, and active inflammatory skin diseases.
- •3.A history of malignancies within the past five years (excluding localized non-melanoma skin cancer).
- •4.Topical corticosteroid treatment (class III or stronger) and/or ultraviolet type B phototherapy within 2 weeks prior to randomization
- •5.Treatment with psoralen plus ultraviolet type A photochemotherapy, methotrexate, cyclosporine, acitretin, or fumaric acid esters within 4 weeks prior to randomization.
- •6.Treatment with adalimumab, etanercept, infliximab, cosentyx, or ixekizumab within 12 weeks, ustekinumab within 24 weeks, or other immunosuppressive or anti-inflammatory agents within 5 half-lives of the active substance prior to the FDG-PET/CT, respectively.
- •7.Scheduled surgery during the trial period (expect minor minimally invasive procedures).
- •8.Systemic infection or fever within 7 days prior to FDG-PET/CT.
- •9.Severe obesity (> 150 kg due to a PET/CT scanner limitation).
- •10.Presence of uncontrolled diabetes mellitus (HbA1c > 75 mmol/mol and/or blood sugar > 11.1 mmol/l and/or clinical judgment).
- •11.History of coagulation defects (clinical judgment).
- •12.Active or latent tuberculosis requiring treatment.
- •13.Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb) or hepatitis C virus antibody (anti-HCV) serology at screening. Subjects with positive HBsAb may be randomised provided they are hepatitis B vaccinated and have negative HBsAg and HBcAb.
- •14.History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at screening, or the subject taking antiretroviral medications as determined by medical history and/or subject’s verbal report.
- •15.No history of varicella zoster infection and negative varicella antibody test (until varicella vaccination is completed).
- •16.History of chronic alcohol or drug abuse within 12 months prior to screening, or any condition associated with poor compliance as judged by the investigator.
- •17.History of intravenous drug use.
- •18.History of attempted suicide or is at significant risk of suicide.
- •19.Major surgery within the past 3 months.
- •20.Pregnancy or lactation (Women of childbearing potential must use a highly effective* form of birth control (confirmed by the investigator) throughout the trial and until 12 weeks after discontinuation of treatment with brodalumab.
- •21.Claustrophobia.
- •22.Reduced renal function (serum creatinine > 200 µmol/L or cr-EDTA clearance < 30 ml/min)
- •23.Any disorder, including but not limited to, cardiovascular, lung, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, immunological, psychiatric, or major physical impairment that is not stable, in the opinion of the investigator, and could:
- •oAffect the safety of the subject throughout the trial.
- •oInfluence the findings of the trial or their interpretations.
- •oImpede the subject’s ability to complete the entire duration of trial.
研究者
相似试验
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, three-way crossover, repeat dose pilot study comparing the effect of inhaled fluticasone furoate/GW642444M combination and fluticasone furoate on the allergen-induced early asthmatic response in subjects with mild asthmaAsthmaEUCTR2009-016581-80-GBGlaxoSmithKline Research & Development Ltd42
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, three-way crossover, repeat dose pilot study comparing the effect of inhaled fluticasone furoate/GW642444M combination and fluticasone furoate on the allergen-induced early asthmatic response in subjects with mild asthmaAsthmaMedDRA version: 12.1Level: LLTClassification code 10001705Term: Allergic asthmaEUCTR2009-016581-80-DEGlaxoSmithKline Research & Development Ltd42
已完成
不适用
A randomised, double-blinded, placebo-controlled trial using cardiovascular magnetic resonance (CMR) scanning to assess remodelling and regression of fibrosis in cardiomyopathy with eplerenoneCardiomyopathyISRCTN23314770Record Provided by the NHSTCT Register - 2007 Update - Department of Health140
进行中（未招募）
1 期
A study of the safety and efficacy of Diclofenac Gel AMZ001 3.06 % for the treatment of knee osteoarthritis symptoms.Knee OsteoarthritisEUCTR2018-001934-16-DKAmzell BV440
进行中（未招募）
1 期
A study of the safety and efficacy of Diclofenac Gel AMZ001 3.06 % for the treatment of knee osteoarthritis symptoms.MedDRA version: 20.0 Level: LLT Classification code 10023476 Term: Knee osteoarthritis System Organ Class: 100000004859Knee OsteoarthritisEUCTR2018-001934-16-CZAmzell BV440